• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Role of p63 in metastasis and therapeutic resistance of bladder cancer

Research Project

Project/Area Number 23501266
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Tumor biology
Research InstitutionTokyo Medical and Dental University

Principal Investigator

KOGA Fumitaka  東京医科歯科大学, 医歯(薬)学総合研究科, 非常勤講師 (10285851)

Project Period (FY) 2011-04-28 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Keywords膀胱癌 / 転移 / 治療抵抗性 / p63 / 化学放射線治療抵抗性 / リスク因子 / 癌幹細胞 / p63
Outline of Final Research Achievements

The following findings were obtained in the present study series and reported in international medical journals. (1) Bladder cancer stem cells are resistant to cisplatin and they lose expression of p63 protein, suggesting that loss of p63 is associated with cisplatin resistance. (2) No significant association was obtained between chemoradiation resistance and p63 expression profile in muscle-invasive bladder cancer. (3)Overexpression of erbB2 in bladder cancer is significantly associated with resistance to chemoradiation and bladder cancer death.

Report

(5 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • 2012 Research-status Report
  • 2011 Research-status Report
  • Research Products

    (10 results)

All 2014 2012 2011 Other

All Journal Article (5 results) (of which Peer Reviewed: 5 results,  Open Access: 1 results) Presentation (5 results) (of which Invited: 1 results)

  • [Journal Article] Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach2014

    • Author(s)
      Inoue M, Koga F, Yoshida S, Tamura T, Fujii Y, Ito E, Kihara K.
    • Journal Title

      Int J Radiat Oncol Biol Phys

      Volume: 90 Issue: 2 Pages: 303-311

    • DOI

      10.1016/j.ijrobp.2014.05.043

    • Related Report
      2014 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells2012

    • Author(s)
      Tatokoro M, Koga F, Yoshida S, Kawakami S, Fujii Y, Neckers L, Kihara K
    • Journal Title

      Int J Cancer

      Volume: 131 Issue: 4 Pages: 987-96

    • DOI

      10.1002/ijc.26475

    • Related Report
      2012 Research-status Report 2011 Research-status Report
    • Peer Reviewed
  • [Journal Article] Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer2012

    • Author(s)
      Yoshida S, Koga F, Kobayashi S, Ishii C, Tanaka H, Tanaka H, Komai Y, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K
    • Journal Title

      Int J Radiat Oncol Biol Phys

      Volume: 83

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Journal Article] ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer2011

    • Author(s)
      Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K
    • Journal Title

      PLoS one

      Volume: 6

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Journal Article] Low-dose Hsp 90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy2011

    • Author(s)
      Yoshida S, Koga F, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K
    • Journal Title

      Cell Cycle

      Volume: 10 Pages: 4291-4299

    • Related Report
      2011 Research-status Report
    • Peer Reviewed
  • [Presentation] Pre-therapeutic risk stratification of muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach2014

    • Author(s)
      Koga F, Inoue M, Kijima T, Yoshida S, Ishioka J, Matsuoka Y, Numao N, Saito K, Masuda H, Fujii Y, Kihara K
    • Organizer
      29th annual EAU congress
    • Place of Presentation
      Stockholm
    • Year and Date
      2014-04-14
    • Related Report
      2014 Annual Research Report
  • [Presentation] Hsp90 阻害剤による膀胱癌幹細胞のシスプラチン抵抗性克服の可能性2012

    • Author(s)
      古賀文隆
    • Organizer
      第7回 Basic Urology Research Seminar
    • Place of Presentation
      大分市
    • Related Report
      2012 Research-status Report
    • Invited
  • [Presentation] Diffusion-weighted MRI predicts sensitivity to chemoradiation in muscle-invasive bladder cancer2012

    • Author(s)
      Koga F, Yoshida S, Kobayashi S, Ishii C, Tanaka Hiroshi, Fujii Y, Tanaka Hajime, Masuda H, Saito K, Komai Y, Kawakami S, Kihara K
    • Organizer
      27th annual EAU congress
    • Place of Presentation
      Paris
    • Related Report
      2011 Research-status Report
  • [Presentation] ErbB2 overexpression predicts chemoradiotherapy resistance and worse prognosis in muscle-invasive bladder cancer patients treated with induction chemoradiotherapy followed by partial or radical cystectomy

    • Author(s)
      井上雅晴、古賀文隆
    • Organizer
      29th European Association of Urology annual meeting
    • Place of Presentation
      ストックホルム(スウェ-デン)
    • Related Report
      2013 Research-status Report
  • [Presentation] Pre-therapeutic risk stratification of muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach

    • Author(s)
      古賀文隆
    • Organizer
      29th European Association of Urology annual meeting
    • Place of Presentation
      ストックホルム(スウェ-デン)
    • Related Report
      2013 Research-status Report

URL: 

Published: 2011-08-05   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi